Replimune Group, Inc.
NASDAQ:REPLBiotechnology
+$0.19 today
- Market cap
- $1.88B
- Beta
- 0.91
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$3.42
Volume 2.13M
Average 7.51M
REPL EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Replimune Group, Inc.NASDAQ: REPL
EBITDA · Q3 FY2026 · quarter ended Dec 2025
EBITDA remains negative
Q3 FY2026 EBITDA was -$67.95M, compared with -$64.95M a year earlier. Trailing-twelve-month EBITDA was -$311.38M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 5 analysts of $0 (+100.0%) for the fiscal year ending Mar 2026, a step up from the -11.5% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$67.95M+17.2% QoQ
- Last fiscal yearMar 2025
- -$253.92M-11.5% YoY
- LTMDec 2025
- -$311.38M-33.2% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -4.6% | +100.0% | +104.6 pp |
| 1 year | -11.5% | +100.0% | +111.5 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (253.92M) USD
- Year-over-year change
- -11.5%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-03-31 | (253.92M) | -11.5% |
| FY2024 | 2024-03-31 | (227.77M) | -32.6% |
| FY2023 | 2023-03-31 | (171.72M) | -50.1% |
| FY2022 | 2022-03-31 | (114.41M) | -49.6% |
| FY2021 | 2021-03-31 | (76.48M) | — |
EBITDA vs competitors
How REPL compares with its peers on the latest reported figures
- REPL's LTM Dec 2025 EBITDA of -$311.38M is the 10th highest of the 11 companies compared; the peer median is -$54.15M.
- Its year-over-year change of -33.2% is the 7th highest of 10, against a peer median of -7.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Aug 2026 | $322.61M | +243.1% | — | 46.0% | |
| LTM Mar 2026 | $127.04M | +256.7% | — | 102.6% | |
| LTM Mar 2026 | $34.88M | +463.6% | — | 48.0% | |
| LTM Jun 2024 | -$36.06M | — | — | 4420.7% | |
| LTM Mar 2026 | -$50.64M | -7.0% | — | 32.2% | |
| LTM Mar 2026 | -$57.67M | -232.5% | — | 162.2% | |
| LTM Mar 2026 | -$112.45M | -48.6% | — | 520.3% | |
| LTM Sep 2026 | -$185.11M | +47.9% | — | 48.8% | |
| LTM Mar 2026 | -$238.99M | -27.7% | — | 770932.3% | |
| LTM Dec 2025 | -$311.38M | -33.2% | — | — | |
| LTM Sep 2026 | -$1.01B | -332.3% | — | 550.8% | |
| Peer median (excluding REPL) | -$54.15M | -7.0% | — | 132.4% | |
Competitors are the stored peer set for REPL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Mar 2021 | FY2022 Mar 2022 | FY2023 Mar 2023 | FY2024 Mar 2024 | FY2025 Mar 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 4.14M | 4.58M | 0 | 0 | 0 |
| Gross Profit | (4.14M) | (4.58M) | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 57.49M | 80.65M | 126.53M | 174.96M | 189.45M |
| Selling, General & Admin | 21.13M | 36.26M | 0 | 0 | 0 |
| Operating Expenses | 78.62M | 116.91M | 177.08M | 234.77M | 261.63M |
| Depreciation & Amortization | 4.14M | 4.58M | 2.45M | 5.08M | 5.93M |
| EBITDA | (76.48M) | (114.41M) | (171.72M) | (227.77M) | (253.92M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (82.76M) | (121.48M) | (177.08M) | (234.77M) | (261.63M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 916K | 390K | 10.01M | 23.36M | 21.12M |
| Interest Expense | 3.06M | 2.22M | 4.16M | 6.66M | 7.89M |
| Other Income / Expenses | (915K) | 278K | 3.08M | 19.39M | 14.8M |
| Income Before Tax | (83.68M) | (121.21M) | (174M) | (215.39M) | (246.83M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | (2.81M) | (3.17M) | 288K | 408K | 468K |
| Net Income | (80.87M) | (118.04M) | (174.28M) | (215.79M) | (247.3M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| EPS (Diluted) | (1.75) | (2.26) | (2.99) | (3.24) | (3.07) |
| Weighted Avg Shares | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
| Weighted Avg Shares (Diluted) | 46.25M | 52.21M | 58.21M | 66.57M | 80.56M |
Replimune Group, Inc.
NASDAQ:REPL
Intrinsic Alpha fair value
Locked
Current Price
$19.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.